Oncology Biosimilar Market Size, Top Share, Demand

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Oncology Biosimilar Market Size Analysis

Global Oncology Biosimilar Market Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Hematopoietic Agents
  1. By Value
4. Granulocyte Colony-Stimulating Factor (G-CSF)
  1. By Value
5. Immunomodulators
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Cervical Cancer
  1. By Value
6. Blood Cancer / Hematological Cancers
  1. By Value
7. Other types (e.g., kidney, stomach, brain cancers)
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous (IV)
  1. By Value
3. Subcutaneous (SC)
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Hematopoietic Agents
  1. By Value
4. Granulocyte Colony-Stimulating Factor (G-CSF)
  1. By Value
5. Immunomodulators
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Cervical Cancer
  1. By Value
6. Blood Cancer / Hematological Cancers
  1. By Value
7. Other types (e.g., kidney, stomach, brain cancers)
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous (IV)
  1. By Value
3. Subcutaneous (SC)
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Others
  1. By Value
U.S.
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Hematopoietic Agents
    1. By Value
  4. Granulocyte Colony-Stimulating Factor (G-CSF)
    1. By Value
  5. Immunomodulators
    1. By Value
2. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Breast Cancer
    1. By Value
  3. Lung Cancer
    1. By Value
  4. Colorectal Cancer
    1. By Value
  5. Cervical Cancer
    1. By Value
  6. Blood Cancer / Hematological Cancers
    1. By Value
  7. Other types (e.g., kidney, stomach, brain cancers)
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous (IV)
    1. By Value
  3. Subcutaneous (SC)
    1. By Value
  4. Others
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Hematopoietic Agents
  1. By Value
4. Granulocyte Colony-Stimulating Factor (G-CSF)
  1. By Value
5. Immunomodulators
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Cervical Cancer
  1. By Value
6. Blood Cancer / Hematological Cancers
  1. By Value
7. Other types (e.g., kidney, stomach, brain cancers)
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous (IV)
  1. By Value
3. Subcutaneous (SC)
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Others
  1. By Value
U.K.
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Hematopoietic Agents
    1. By Value
  4. Granulocyte Colony-Stimulating Factor (G-CSF)
    1. By Value
  5. Immunomodulators
    1. By Value
2. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Breast Cancer
    1. By Value
  3. Lung Cancer
    1. By Value
  4. Colorectal Cancer
    1. By Value
  5. Cervical Cancer
    1. By Value
  6. Blood Cancer / Hematological Cancers
    1. By Value
  7. Other types (e.g., kidney, stomach, brain cancers)
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous (IV)
    1. By Value
  3. Subcutaneous (SC)
    1. By Value
  4. Others
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Hematopoietic Agents
  1. By Value
4. Granulocyte Colony-Stimulating Factor (G-CSF)
  1. By Value
5. Immunomodulators
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Cervical Cancer
  1. By Value
6. Blood Cancer / Hematological Cancers
  1. By Value
7. Other types (e.g., kidney, stomach, brain cancers)
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous (IV)
  1. By Value
3. Subcutaneous (SC)
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Others
  1. By Value
China
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Hematopoietic Agents
    1. By Value
  4. Granulocyte Colony-Stimulating Factor (G-CSF)
    1. By Value
  5. Immunomodulators
    1. By Value
2. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Breast Cancer
    1. By Value
  3. Lung Cancer
    1. By Value
  4. Colorectal Cancer
    1. By Value
  5. Cervical Cancer
    1. By Value
  6. Blood Cancer / Hematological Cancers
    1. By Value
  7. Other types (e.g., kidney, stomach, brain cancers)
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous (IV)
    1. By Value
  3. Subcutaneous (SC)
    1. By Value
  4. Others
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Hematopoietic Agents
  1. By Value
4. Granulocyte Colony-Stimulating Factor (G-CSF)
  1. By Value
5. Immunomodulators
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Cervical Cancer
  1. By Value
6. Blood Cancer / Hematological Cancers
  1. By Value
7. Other types (e.g., kidney, stomach, brain cancers)
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous (IV)
  1. By Value
3. Subcutaneous (SC)
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Others
  1. By Value
UAE
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Hematopoietic Agents
    1. By Value
  4. Granulocyte Colony-Stimulating Factor (G-CSF)
    1. By Value
  5. Immunomodulators
    1. By Value
2. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Breast Cancer
    1. By Value
  3. Lung Cancer
    1. By Value
  4. Colorectal Cancer
    1. By Value
  5. Cervical Cancer
    1. By Value
  6. Blood Cancer / Hematological Cancers
    1. By Value
  7. Other types (e.g., kidney, stomach, brain cancers)
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous (IV)
    1. By Value
  3. Subcutaneous (SC)
    1. By Value
  4. Others
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product Type
1. Introduction
  1. Product Type By Value
2. Monoclonal Antibodies (mAbs)
  1. By Value
3. Hematopoietic Agents
  1. By Value
4. Granulocyte Colony-Stimulating Factor (G-CSF)
  1. By Value
5. Immunomodulators
  1. By Value
By Cancer Type
1. Introduction
  1. Cancer Type By Value
2. Breast Cancer
  1. By Value
3. Lung Cancer
  1. By Value
4. Colorectal Cancer
  1. By Value
5. Cervical Cancer
  1. By Value
6. Blood Cancer / Hematological Cancers
  1. By Value
7. Other types (e.g., kidney, stomach, brain cancers)
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous (IV)
  1. By Value
3. Subcutaneous (SC)
  1. By Value
4. Others
  1. By Value
By Distribution Channel
1. Introduction
  1. Distribution Channel By Value
2. Hospital Pharmacies
  1. By Value
3. Retail Pharmacies
  1. By Value
4. Online Pharmacies
  1. By Value
5. Others
  1. By Value
Brazil
1. By Product Type
  1. Introduction
    1. Product Type By Value
  2. Monoclonal Antibodies (mAbs)
    1. By Value
  3. Hematopoietic Agents
    1. By Value
  4. Granulocyte Colony-Stimulating Factor (G-CSF)
    1. By Value
  5. Immunomodulators
    1. By Value
2. By Cancer Type
  1. Introduction
    1. Cancer Type By Value
  2. Breast Cancer
    1. By Value
  3. Lung Cancer
    1. By Value
  4. Colorectal Cancer
    1. By Value
  5. Cervical Cancer
    1. By Value
  6. Blood Cancer / Hematological Cancers
    1. By Value
  7. Other types (e.g., kidney, stomach, brain cancers)
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous (IV)
    1. By Value
  3. Subcutaneous (SC)
    1. By Value
  4. Others
    1. By Value
4. By Distribution Channel
  1. Introduction
    1. Distribution Channel By Value
  2. Hospital Pharmacies
    1. By Value
  3. Retail Pharmacies
    1. By Value
  4. Online Pharmacies
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Oncology Biosimilar Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Pfizer Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Amgen Inc.
Novartis International AG
Biocon Ltd.
Reddy’s Laboratories
Samsung Bioepis
Mylan N.V. (now part of Viatris)
Allergan (AbbVie)
STADA Arzneimittel AG
Apotex Inc.
Roche (via biosimilar affiliates)
Sandoz (Novartis division)
Celltrion Inc.
Bio-Thera Solutions
Organon (via acquired biosimilar rights)
Teva Pharmaceuticals

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment